November 30, 2005 – PIramed of the UKsigned a deal worth up to $230 million with Genentech to develop new cancer drugs; in an agreement worth up to $560 million, BioCryst gave Roche the right to develop its immune suppressant; Discovery Partners International will end its 10-year with Pfizer and close its South San Francisco facility; Gilead Sciences signed a licensing deal with 4AZA Bioscience of Belgium to develop compounds for hepatitis C; Schering-Plough received FDA approval of a sixth indication for its antibiotic, Avelox; GlaxoSmithKline updated its pipeline of cancer drugs, and Visicu filed for its IPO. The Centient Biotech 200™ was up less than 1 point at 3926.45, a rise of .02%. More details...
